Atomoxetine in the Management of Children with ADHD: Effects on Quality of Life and School Functioning

Abstract

The purpose of this study was to examine in a controlled trial the effects of atomoxetine on the management of attention deficit-hyperactivity disorder (ADHD) symptoms and functional impairments at school and at home. Participants were 153 children (age 8 to 12 years) diagnosed with attention-deficit hyperactivity disorder who were randomized to double-blind treatment with either atomoxetine (n = 101) or placebo (n = 52). Findings revealed significant improvements both for parent and teacher ratings of behavior for children receiving atomoxetine therapy. Children also were reported to evidence a trend toward better response to active medication than to placebo for health-related quality of life as rated by parents. No significant effects were revealed for the teacher ratings of academic productivity. Data were interpreted to provide support for the efficacy of atomoxetine on the symptoms associated with ADHD. The effects of atomoxetine on other functional outcomes including academic performance and health-related outcomes are of interest, albeit less compelling for this particular investigation, than for the effects on overt symptom display.

Get full access to this article

View all access options for this article.

References

American Academy of Pediatrics on Quality Improvement Subcommittee on Attention-Deficit/Hyperactivity Disorder . Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105: 1158-1170.

American Academy of Pediatrics on Quality Improvement Subcommittee on Attention-Deficit/Hyperactivity Disorder . Clinical practice guideline: treatment of the school-age child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108: 1033-1044.

Brown RT , Freeman WS. Primary care. In: Marsh DT , Fristad MA (eds). Handbook of Serious Emotional Disturbance in Children and Adolescents. New York: Wiley; 2002:428-444.

Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Clin North Am. 2000;3: 481-498.

Spencer T , Biederman J , Wilens T , Farone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 2002;63(Suppl 12): 16-22.

Weiss M , Tannock R , Kratochvil C , et al. A randomized placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Indianapolis, Ind: Lilly Corporate Center; 2004.

Perwien AR , Faries DE , Kratochvil CJ , et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. J Dev Behav Pediatr. 2004;25: 264-271.

Matza LS , Rentz AM , Secnik K , et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25: 166-174.

Psychological Corporation . Wechsler Abbreviated Scales of Intelligence. San Antonio: Author, 1993.

10.

American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Author; 1994.

11.

Ambrosini PJ. Historical development and present status of the Schedule for Affective Disorders and Schizophrenia for school-age children (K-SADS). J Am Acad Child Adolesc Psychiatry. 2000;39: 49-58.

12.

DuPaul GJ , Power TJ , Anastopoulos AD , Reid R. ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretations. New York: Guilford; 1998.

13.

DuPaul GJ , Rapport MD , Perriello LM. Teacher Rating Scales of Academic Skills: the development of the academic performance rating scale. School Psychol Rev. 1991;20: 284-300.

14.

Conners CK. Conners’ Rating Scales: Revised Technical Manual. North Towanda, NY: Multi-Health Systems; 1997.

15.

Phelps L , Brown RT , Powers TJ. Pediatric Psychopharmacology: Facilitating Collaborative practices. Washington, DC: American Psychological Association; 2001.

16.

Landgraf J , Abetz L , Ware JE. The CHQ User’s Manual. Boston: Health Institute; 1996.

17.

Spencer T , Biederman J , Wilens T , Farone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002; 63(Suppl 12): 3-9.

18.

Brown RT , Dingle AD , Dreelin E. Neuropsychological effects of stimulant medication on children’s learning and behavior. In: Reynolds CR , Fletcher-Janzen E (eds). Handbook of Clinical Neuropsychology. New York: Plenum; 1997.

19.

Bennett F , Brown RT , Craver J , Anderson D. Stimulant medication for the child with attention-deficit/hyper-activity disorder. Pediatr Clin North Am. 1999;46: 929-944.

20.

Brown RT , LaRosa A. Recent developments in the pharmacotherapy of attention-deficit/hyperactivity disorder. Professional Psychology Research and Practice. 2002;33: 591-595.

21.

Brown RT , Sammons M. Pediatric Psychopharmacology: a review of new developments and recent research. Professional Psychology Research and Practice. 2002;33: 135-147.

22.

Michelson D , Faries D , Wernicke J , et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized placebo-controlled, dose-response study. Pediatrics. 2001;108: 1-9.

23.

Michelson D , Buitelaar J. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43: 895-904.